{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}],"title":"AE"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"}],"title":"PD"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}],"title":"Other"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"7"}],"title":"Participants censored"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"8"}],"units":"Participants"}],"description":"OS was defined as the time interval from the first dose of study treatment to death from any cause. Participants who were lost to follow-up or survived until the end of the study were censored at the last date that they were known to be alive. Medians, Q1, and Q3 of OS and the proportion of participants who were alive at 3, 6, 9, and 12 months from Study Day 1 were derived using KM methods.","groups":[{"description":"Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG000","title":"Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG001","title":"Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG002","title":"Cohort 12 - Gastric (Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG003","title":"Cohort 3A - Gastric (TTX-030 + mFOLFOX6)"},{"description":"Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.","id":"OG004","title":"Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)"},{"description":"Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"OG005","title":"Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"OG006","title":"Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG007","title":"Cohort 4 - CRC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG008","title":"Cohort 6 - HNSCC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG009","title":"Cohort 8 - GEC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG010","title":"Cohort 10 - UCC (TTX-030 + Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants with events (death)","reportingStatus":"POSTED","timeFrame":"Through study completion, an average of 1 year","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}